As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

Kruif de Kruif Biography and Net Worth

SVP of Merus

Presently, John de Kruif holds the position of Chief Technology Officer & Senior Vice President at Merus NV.

In the past he was Director-Antibody Discovery at Crucell NV.

He received a doctorate from the University of Utrecht.

What is Kruif de Kruif's net worth?: The estimated net worth of Kruif de Kruif is at least $679,581.90 as of August 12th, 2021. Mr. de Kruif owns 15,830 shares of Merus stock worth more than $679,582 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. de Kruif may own. Additionally, Mr. de Kruif receives a salary of $350,850.00 as SVP at Merus. Learn More about Kruif de Kruif's net worth.
How old is Kruif de Kruif?: Mr. de Kruif is currently 59 years old. There are 5 older executives and no younger executives at Merus. The oldest executive at Merus is Mr. Gregory D. Perry, Chief Financial Officer, who is 64 years old. Learn More on Kruif de Kruif's age.
What is Kruif de Kruif's salary?: As the SVP of Merus, Mr. de Kruif earns $350,850.00 per year. There are 4 executives that earn more than Mr. de Kruif. The highest earning executive at Merus is Dr. Sven Ante Lundberg M.D., CEO, President & Executive Director, who commands a salary of $953,060.00 per year. Learn More on Kruif de Kruif's salary.
How do I contact Kruif de Kruif?: The corporate mailing address for Mr. de Kruif and other Merus executives is YALELAAN 62, UTRECHT P7, 3584 CM. Merus can also be reached via phone at (130) 253-8800 and via email at [email protected]. Learn More on Kruif de Kruif's contact information.
Has Kruif de Kruif been buying or selling shares of Merus?: Kruif de Kruif has not been actively trading shares of Merus during the past quarter. Most recently, Kruif John De sold 2,787 shares of the business's stock in a transaction on Thursday, August 12th. The shares were sold at an average price of $19.34, for a transaction totalling $53,900.58. Following the completion of the sale, the senior vice president now directly owns 15,830 shares of the company's stock, valued at $306,152.20. Learn More on Kruif de Kruif's trading history.
Who are Merus' active insiders?: Merus' insider roster includes Lex Bakker (SVP), Kruif de Kruif (SVP), Sven Lundberg (President, Chief Executive Officer, Executive Director), and Peter Silverman (EVP, Chief Operating Officer, & General Counsel). Learn More on Merus' active insiders.
Are insiders buying or selling shares of Merus?: In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 47,376 shares worth more than $1,969,643.70. The most recent insider tranaction occured on June, 27th when COO Peter B. Silverman sold 10,000 shares worth more than $600,000.00. Insiders at Merus own 4.6% of the company. Learn More about insider trades at Merus.
Information on this page was last updated on 6/27/2024.

Kruif de Kruif Insider Trading History at Merus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/12/2021	Sell	2,787	$19.34	$53,900.58	15,830

Kruif de Kruif Buying and Selling Activity at Merus

Merus Company Overview

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Today's Range

Now: $44.86

$43.20

$45.76

50 Day Range

MA: $50.58

$42.93

$54.50

2 Week Range

Now: $44.86

$22.26

$61.61

Volume

660,205 shs

Average Volume

682,577 shs

Market Capitalization

$3.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Kruif de Kruif Biography and Net Worth

What is Kruif de Kruif's net worth?

How old is Kruif de Kruif?

What is Kruif de Kruif's salary?

How do I contact Kruif de Kruif?

Has Kruif de Kruif been buying or selling shares of Merus?

Who are Merus' active insiders?

Are insiders buying or selling shares of Merus?